cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Year: 2019
Type: article
Source: Annals of Oncology
Authors: S.K. Pal, D.F. Bajorin, J.H. Hoffman-Censits, D.I. Quinn, D.P. Petrylak, M.D. Galsky, U.N. Vaishampayan, U. De Giorgi, S. Gupta, H.A. Burris, H.S. Soifer, G. Li, C.L. Dambkowski, S. Moran, H. Wang, S. Daneshmand, J.E. Rosenberg
Institutions: City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Yale Cancer Center, Smilow Cancer Hospital, Icahn School of Medicine at Mount Sinai, Wayne State University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Huntsman Cancer Institute, University of Utah Health Care, Sarah Cannon, Keck Hospital of USC
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, University of Southern California, Celgene, Endocyte, Regeneron Pharmaceuticals, Exelixis, Celldex Therapeutics, TG Therapeutics, PTC Therapeutics, Clovis Oncology, Five Prime Therapeutics, INOVIO Pharmaceuticals, Agios Pharmaceuticals, HCA Healthcare, Jounce Therapeutics, Mersana Therapeutics, Mirati Therapeutics, Incyte, Tarveda Therapeutics, Jiangsu Hengrui Medicine, Revolution Medicines, Moderna, UroGen Pharma, MacroGenics, Institut National de la Santé et de la Recherche Médicale, Eisai, Astellas Pharma, Fidia Farmaceutici, Ipsen, Genentech, EMD Serono, Chugai Pharmaceutical, Pharmacyclics, Sanofi Pasteur, Foundation Medicine, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W2977915048